Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Solid Tumor Drugs Market by Type (Small Molecules, Biologics) and by Application (Oncology, Radiology, Neurology, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02258

Pages: NA

Charts: NA

Tables: NA

Solid tumors are abnormal mass of tissues that do not comprise any cyst or liquid areas within them. These tumors are of two types, i.e. benign (non-cancerous) and malignant (cancerous). These tumors comprise lymphomas, carcinomas, sarcomas, and melanomas. Most of the solid tumors are treated using radiotherapy, chemotherapy, and/or surgery.

The global solid tumor drugs market is driven by rise in prevalence of different forms of metastatic cancers, increase in the demand for highly effective chemotherapeutic agents, and exposure to risk factors such as alcohol consumption and obesity. However, high cost of therapy and associated side effects such as skin reactions, anemia, and hair loss hamper the market growth. However, advancements in treatment techniques, such as targeted and combination therapies, which include Kadcyla and Herceptin for breast cancer provide growth opportunities for the market growth.

The global solid tumor drugs market is segmented based on type, application, and region. Based on type, it is bifurcated into small molecules and biologics. On the basis of application, it is divided into oncology, radiology, and neurology. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major players operating in this market are AstraZeneca, Abbott Laboratories, Amgen Limited & Amgen Ireland Limited, Biogen, Baxter, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc., Celgene Corporation, and Pfizer Inc.

Key Benefits

  • The report presents the market analysis of the global solid tumor market along with the regional trend and future estimations.
  • It provides extensive information about the market segments to understand the market dynamics.
  • The key factors that drive, hamper, or provide opportunities to the market are provided in the report
  • Competitive landscape of the industry along with the profile analysis of market players is provided in the report.

 Key Market Segments

  • By Type
    • Small Molecules
    • Biologics
      • Enzymes
      • Blood and Blood Components
      • Gene Therapy
      • Recombinant Proteins
      • Somatic Cells
      • Tissues
      • Vaccines
  • By Application
    • Oncology
    • Radiology
    • Neurology
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • AstraZeneca
  • Amgen Limited & Amgen Ireland Limited
  • Eli Lilly and Company
  • Pfizer Inc.
  • Biogen
  • GlaxoSmithKline plc.
  • Abbott Laboratories
  • Baxter
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Celgene Corporation

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: SOLID TUMOR DRUGS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Small Molecules

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Biologics

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Enzymes

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Blood and Blood Components

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Gene Therapy

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Recombinant Proteins

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Somatic Cells

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Tissues

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Vaccines

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: SOLID TUMOR DRUGS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Oncology

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Radiology

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Neurology

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: SOLID TUMOR DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Solid Tumor Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Solid Tumor Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Solid Tumor Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Solid Tumor Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Solid Tumor Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Solid Tumor Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Solid Tumor Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Solid Tumor Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Solid Tumor Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Solid Tumor Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Solid Tumor Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Solid Tumor Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Solid Tumor Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Solid Tumor Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Solid Tumor Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Solid Tumor Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Solid Tumor Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Solid Tumor Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Solid Tumor Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Solid Tumor Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Solid Tumor Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Solid Tumor Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Solid Tumor Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Solid Tumor Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Solid Tumor Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. AstraZeneca

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Abbott Laboratories

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Amgen Limited And Amgen Ireland Limited

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Biogen

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Baxter

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Bristol-Myers Squibb Company

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. F. Hoffmann-La Roche Ltd.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Eli Lilly And Company

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Johnson And Johnson

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. GlaxoSmithKline Plc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

    • 8.11. Celgene Corporation

      • 8.11.1. Company Overview

      • 8.11.2. Key Executives

      • 8.11.3. Company Snapshot

      • 8.11.4. Operating Business Segments

      • 8.11.5. Product Portfolio

      • 8.11.6. Business Performance

      • 8.11.7. Key Strategic Moves and Developments

    • 8.12. Pfizer Inc.

      • 8.12.1. Company Overview

      • 8.12.2. Key Executives

      • 8.12.3. Company Snapshot

      • 8.12.4. Operating Business Segments

      • 8.12.5. Product Portfolio

      • 8.12.6. Business Performance

      • 8.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL SOLID TUMOR DRUGS MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL SOLID TUMOR DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL SOLID TUMOR DRUGS MARKET FOR BIOLOGICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL SOLID TUMOR DRUGS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL SOLID TUMOR DRUGS MARKET FOR ONCOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL SOLID TUMOR DRUGS MARKET FOR RADIOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL SOLID TUMOR DRUGS MARKET FOR NEUROLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL SOLID TUMOR DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL SOLID TUMOR DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA SOLID TUMOR DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 13. U.S. SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 14. U.S. SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. CANADA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 16. CANADA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE SOLID TUMOR DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. ITALY SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. ITALY SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. UK SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. UK SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC SOLID TUMOR DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. CHINA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. CHINA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. INDIA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. INDIA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA SOLID TUMOR DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. UAE SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. UAE SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA SOLID TUMOR DRUGS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA SOLID TUMOR DRUGS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 73. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 74. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 75. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 76. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 78. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 79. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 80. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 81. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. AMGEN LIMITED AND AMGEN IRELAND LIMITED: KEY EXECUTIVES
  • TABLE 83. AMGEN LIMITED AND AMGEN IRELAND LIMITED: COMPANY SNAPSHOT
  • TABLE 84. AMGEN LIMITED AND AMGEN IRELAND LIMITED: OPERATING SEGMENTS
  • TABLE 85. AMGEN LIMITED AND AMGEN IRELAND LIMITED: PRODUCT PORTFOLIO
  • TABLE 86. AMGEN LIMITED AND AMGEN IRELAND LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. BIOGEN: KEY EXECUTIVES
  • TABLE 88. BIOGEN: COMPANY SNAPSHOT
  • TABLE 89. BIOGEN: OPERATING SEGMENTS
  • TABLE 90. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 91. BIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. BAXTER: KEY EXECUTIVES
  • TABLE 93. BAXTER: COMPANY SNAPSHOT
  • TABLE 94. BAXTER: OPERATING SEGMENTS
  • TABLE 95. BAXTER: PRODUCT PORTFOLIO
  • TABLE 96. BAXTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 101. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 103. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 104. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 105. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 106. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 108. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 109. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 110. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 111. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 113. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 114. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 115. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 116. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 118. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 119. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 120. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 121. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. CELGENE CORPORATION: KEY EXECUTIVES
  • TABLE 123. CELGENE CORPORATION: COMPANY SNAPSHOT
  • TABLE 124. CELGENE CORPORATION: OPERATING SEGMENTS
  • TABLE 125. CELGENE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 126. CELGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. PFIZER INC.: KEY EXECUTIVES
  • TABLE 128. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 129. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 130. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 131. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL SOLID TUMOR DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL SOLID TUMOR DRUGS MARKET
  • FIGURE 3. SEGMENTATION SOLID TUMOR DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN SOLID TUMOR DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALSOLID TUMOR DRUGS MARKET
  • FIGURE 11. SOLID TUMOR DRUGS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. SOLID TUMOR DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. SOLID TUMOR DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. SOLID TUMOR DRUGS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. SOLID TUMOR DRUGS MARKET FOR ONCOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. SOLID TUMOR DRUGS MARKET FOR RADIOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. SOLID TUMOR DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. SOLID TUMOR DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: SOLID TUMOR DRUGS MARKET
  • FIGURE 25. TOP PLAYER POSITIONING, 2024
  • FIGURE 26. ASTRAZENECA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. ASTRAZENECA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. AMGEN LIMITED AND AMGEN IRELAND LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. AMGEN LIMITED AND AMGEN IRELAND LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. AMGEN LIMITED AND AMGEN IRELAND LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. BIOGEN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. BIOGEN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. BIOGEN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. BAXTER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. BAXTER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. BAXTER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. ELI LILLY AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. GLAXOSMITHKLINE PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. CELGENE CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. CELGENE CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. CELGENE CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Solid Tumor Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved